CHARACTERIZE CANCER
Methylation signatures using
cfDNA can accurately distinguish neuroendocrine prostate cancer (NEPC) from prostate adenocarcinoma (PAC), often missed through routine clinical care.¹
Apply methylation signature
to stratify patients:
Evaluate patient response to
ARSi based on cancer subtypes¹:
Median overall survival after metastasis¹
ARSi, androgen receptor signaling inhibitor; cfDNA, cell-free DNA; CRPC, castration-resistant prostate cancer.
Methylation
signatures can lead to more accurate personalized medicine and predict patient response to treatment.¹
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma